Spinal CordNCT06548776
Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord
A study testing Magnetic Resonance Spectroscopy (MRS) Scan in people with Spinal Cord, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To learn if MRS can effectively assess spinal cord lesions. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Spinal Cord
- What is being tested?
- Magnetic Resonance Spectroscopy (MRS) Scan
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Sep 2024to 25 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Volunteers:
- Adults > 18 years
- Healthy with no malignancy, demyelinating disease, back pain, degenerative disease, or spinal cord lesions.
- Consent able patients.
- Patients with low volume LMD to receive treatment CNS radiation:
- Adults > 18 years old.
Show all 11Show fewer
- MR or CSF with evidence of LMD.
- Patients to receive CSI as part of standard treatment of LMD disease.
- Consent able patients, willingness and ability to comply with the study procedures.
- No spinal cord lesions only LMD disease
- Recruitment by radiation oncology faculty in consultation with Dr. De. . .
Who cannot join
- Volunteers:
- Age < 18 years
- Pregnant or breastfeeding individuals.
- History of cancer.
- History of spinal cord lesions including malignant, demyelinating, or inflammatory.
- History of prior spinal surgery.
Show all 18Show fewer
- History of implantable devices.
- History of MR claustrophobia.
- Degenerative disease or spinal/back pain including myelopathy and radiculopathy.
- Scoliosis.
- Patients with LMD:
- Age < 18 years
- History of spinal cord lesions including malignant, demyelinating, or inflammatory.
- History of prior spinal surgery.
- History of implantable devices.
- History of MR claustrophobia.
- Degenerative disease or spinal/back pain including myelopathy and radiculopathy.
- Scoliosis.
Trial locations and contacts
1 site in 1 country.
About this study
To learn if MRS can effectively assess spinal cord lesions.
Read the detailed description
Primary Objective:
Establish the feasibility and spectrum of MRS for adult patients while mapping the total spine spectrum at short TEs to allow for future comparison with patients to assess spinal cord lesions malignant potential and grade.
Secondary Objective:
Test success of the spectrum by implementing the protocol on 3 low volume LMD receiving LMD receiving CSI. This will allow us to test reproducibility of the protocol and test effect of radiation on spinal cord at different time frames. This will serve as secondary data for subsequent trials targeting functional statues after radiation and tumor grading predictability of MRS.
- Conditions
- Spinal Cord
- Being tested
- Magnetic Resonance Spectroscopy (MRS) Scan
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnetic Resonance Spectroscopy (MRS) ScanDiagnostic test
Participants will receive MRS Scan
| Study group | Role | What they receive |
|---|---|---|
| Healthy Volunteers | Experimental | Participants will be recruited from DI volunteer pool to implement MRS spine on. Receives: Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) Scan |
| Patients | Experimental | Participants will be recruited from DI volunteer pool to implement MRS spine on. Receives: Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) Scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
Measured: Through study completion; an average of 1 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2024
- Study start4 Sep 2024
- Primary completion25 Aug 2026
- Study completion25 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Spinal CordStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Rami Eldaya, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06548776
- Sponsor's protocol ID
- 2024-0249
- Other IDs
- NCI-2024-06761
- Status last verified
- Aug 2026
- First submitted
- 8 Aug 2024
- Last updated
- 31 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord
- ClinicalTrials.gov ID
- NCT06548776
- Acronym / sponsor ID
- 2024-0249
- Conditions
- Spinal Cord
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 4 Sep 2024 (actual)
- Primary completion
- 25 Aug 2026 (actual)
- Study completion
- 25 Aug 2026 (actual)
- First posted
- 12 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To learn if MRS can effectively assess spinal cord lesions.
Detailed description
Primary Objective:
Establish the feasibility and spectrum of MRS for adult patients while mapping the total spine spectrum at short TEs to allow for future comparison with patients to assess spinal cord lesions malignant potential and grade.
Secondary Objective:
Test success of the spectrum by implementing the protocol on 3 low volume LMD receiving LMD receiving CSI. This will allow us to test reproducibility of the protocol and test effect of radiation on spinal cord at different time frames. This will serve as secondary data for subsequent trials targeting functional statues after radiation and tumor grading predictability of MRS.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Healthy Volunteers | Experimental | Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) ScanParticipants will be recruited from DI volunteer pool to implement MRS spine on. |
| Patients | Experimental | Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) ScanParticipants will be recruited from DI volunteer pool to implement MRS spine on. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Adults > 18 years
- Healthy with no malignancy, demyelinating disease, back pain, degenerative disease, or spinal cord lesions.
- Consent able patients.
- Adults > 18 years old.
- MR or CSF with evidence of LMD.
Key exclusion criteria (18 listed)
- Age < 18 years
- Pregnant or breastfeeding individuals.
- History of cancer.
- History of spinal cord lesions including malignant, demyelinating, or inflammatory.
- History of prior spinal surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnetic Resonance Spectroscopy (MRS) ScanParticipants will receive MRS Scan | Diagnostic test | Healthy Volunteers, Patients |
Primary outcome
Safety and Adverse Events (AEs)
Time frame: Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2026.
- MD Anderson Cancer Center WebsiteLink provided by the sponsor.
Related trials for Spinal Cord
Active, not recruitingPhase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Muscular Atrophy, Spinal
Recruiting
MyHand-SCI: An Active Hand Orthosis for Spinal Cord Injury
Spinal Cord Injuries, Tetraplegia
RecruitingPhase 1/2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
Amyotrophic Lateral Sclerosis
Not yet recruiting
A Study on the Addition of Alsum30 for the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), Bacillus Coagulans
Active, not recruiting
Functional Outcomes and Control Using Synchron BCI - Australia
Neurologic Disorder, Neurologic Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rami Eldaya, MD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Magnetic Resonance Spectroscopy (MRS) Scan in people with Spinal Cord, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Adverse Events (AEs) (time frame: Through study completion; an average of 1 year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.